Last reviewed · How we verify
NCT07085221
Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock
NA trial testing hospital external management in Shock, Cardiogenic in 472 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 472 |
| Start date | 19 November 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- hospital external management
Conditions studied
- Shock, Cardiogenic — all drugs for Shock, Cardiogenic →
- Shock — all drugs for Shock →
Sponsor
Renmin Hospital of Wuhan University
Who can join
18 and older, any sex, with Shock, Cardiogenic or Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study was a multi-center, open-label, randomized controlled clinical trial. A total of 472 patients with early-stage cardiogenic shock were recruited and randomly divided into the experimental group and the control group, with 236 cases in each group. The HeartMed-HF digital out-of-hospital management was used to manage the patients in the experimental group, while the patients in the control group were managed according to the discharge guidance. The primary endpoints were 1-year all-cause mortality and unplanned readmission after randomization (excluding emergency department visits). Secondary endpoints (at 3 months, 6 months, and 12 months post-randomization) were: all-cause mortality, rehospitalization for HF, recurrent MI, ischemia-driven repeat revascularization, stroke, BARC 3-5 grade major bleeding, unplanned formal rehospitalization, types of GDMT medications or GDMT target dose achievement rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07085221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Shock, Cardiogenic
Currently open trials in the same condition.
- NCT06832722 — Procizumab (PCZ; AK1967) in Critical Cardiovascular Care · Phase 1, PHASE2 · recruiting
- NCT06766006 — ECMO LEft Ventricle UNloading Strategy · recruiting
- NCT05669183 — Hemodynamic Comparison of Peripheral and Central VA ECMO. · recruiting
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
- NCT06656962 — The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07085221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: 25 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing